uniQure NV (QURE) Shares Down 4.6%
uniQure NV (NASDAQ:QURE) shares dropped 4.6% during mid-day trading on Tuesday . The stock traded as low as $8.46 and last traded at $8.47, with a volume of 124,563 shares traded. The stock had previously closed at $8.88.
QURE has been the topic of several research reports. Cowen and Company reiterated a “buy” rating on shares of uniQure NV in a research report on Tuesday, June 14th. Piper Jaffray Cos. reiterated a “buy” rating on shares of uniQure NV in a research report on Monday, June 13th. Leerink Swann reiterated a “buy” rating on shares of uniQure NV in a research report on Sunday, June 12th. Jefferies Group reiterated a “buy” rating on shares of uniQure NV in a research report on Tuesday, May 31st. Finally, Oppenheimer Holdings Inc. reiterated a “buy” rating on shares of uniQure NV in a research report on Tuesday, May 31st. One equities research analyst has rated the stock with a sell rating and ten have given a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and a consensus target price of $28.10.
The firm’s 50 day moving average price is $7.86 and its 200 day moving average price is $11.35. The stock’s market cap is $209.47 million.
uniQure NV (NASDAQ:QURE) last issued its quarterly earnings results on Tuesday, May 31st. The company reported ($0.93) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.82) by $0.10. Analysts predict that uniQure NV will post ($3.50) earnings per share for the current fiscal year.
Uniqure NV is a pharmaceutical company based in the Netherlands. It is primarily engaged in the field of gene therapy for orphan diseases. The Company is focused on patients suffering from genetic or acquired diseases by directing the expression of a therapeutic protein or restoring the expression of a missing protein through a single administration.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.